Amuvatinib (MP470) inhibits PDGFR, c-Kit, and c-MET [94] in preclinical studies: MP470 combined with erlotinib inhibits prostate cancer cell proliferation and tumor xenograft growth [95], and MP470 treatment sensitizes glioblastoma cells to radiotherapy in mice [96]. Here, MET is linked to neoplasm.